Community-acquired pneumonia (CAP), defined as pneumonia contracted outside of hospitals or extended care facilities, remains one of the leading causes of hospitalization and mortality across Europe. With incidence rates ranging from 1.6 to 10.8 cases per 1,000 adults annually, CAP imposes a substantial burden on healthcare systems, particularly among older adults and those with comorbidities. Severe cases can lead to respiratory failure, sepsis, and mortality rates exceeding 30% in intensive care settings. Recent Greek research, spearheaded by leading universities, has illuminated a promising pathway to improve outcomes through the immunomodulatory properties of clarithromycin, a macrolide antibiotic long used for its antimicrobial effects but now validated for its role in modulating the immune response.
A groundbreaking analysis published in eBioMedicine on April 3, 2026, delves into the molecular mechanisms behind clarithromycin's benefits in CAP, building on the landmark ACCESS trial. This collaboration among Greek academic institutions and hospitals reveals how adding oral clarithromycin to standard beta-lactam antibiotics not only accelerates clinical recovery but also targets key inflammatory pathways, potentially reshaping treatment protocols continent-wide.
Understanding Community-Acquired Pneumonia in the European Context
CAP arises from bacterial, viral, or atypical pathogens inhaled into the lungs, triggering an intense inflammatory response that can escalate to acute respiratory distress syndrome (ARDS) or sepsis. In Europe, post-pandemic surveillance shows fluctuating incidence, with a notable decline during non-pharmaceutical interventions (NPIs) to 24.2 per 1,000 person-years, rebounding thereafter. The elderly bear the brunt, with mortality linked to dysregulated immunity—excessive cytokine storms or immunoparalysis leading to secondary infections.
Current European Respiratory Society (ERS) and ESCMID guidelines recommend beta-lactams as first-line for hospitalized CAP, with macrolides like clarithromycin added for severe cases or atypical coverage. However, emerging evidence underscores macrolides' non-antimicrobial benefits, including reduced neutrophil infiltration and cytokine modulation, independent of pathogen eradication. This new Greek study provides mechanistic proof, positioning clarithromycin as a strategic adjunct.
The ACCESS Trial: Pivotal Clinical Evidence from Greece
Launched in 2021 amid the COVID-19 era, the ACCESS trial (NCT04724044) was a phase 3, double-blind, randomized controlled trial across 18 Greek public hospitals. It enrolled 278 adults hospitalized with CAP, exhibiting systemic inflammatory response syndrome (SIRS), Sequential Organ Failure Assessment (SOFA) score ≥2, and procalcitonin ≥0.25 ng/mL. Participants received standard-of-care (SoC) beta-lactams plus either oral clarithromycin (500 mg twice daily for 7 days) or placebo.
The primary composite endpoint at 72 hours—≥50% improvement in respiratory symptoms plus ≥30% SOFA reduction or favorable procalcitonin kinetics—was achieved by 68% in the clarithromycin arm versus 38% in placebo (OR 3.40, p<0.0001). Benefits included fewer progressions to respiratory failure (6% vs. 17%), mechanical ventilation needs, and 28-day mortality trends (8% vs. 17%). Serious adverse events were similar, with no treatment attributions. This established clarithromycin's early anti-inflammatory role, prompting the molecular deep-dive.
Breakthrough Molecular Analysis in eBioMedicine
The 2026 eBioMedicine paper analyzes ACCESS biosamples from 86 patients using RNA sequencing of peripheral blood mononuclear cells (PBMCs) and ex vivo cytokine stimulation. Differential gene expression (DEG) via DESeq2, Gene Ontology (GO), and Reactome pathways revealed clarithromycin's three-pronged action: IL-1 pathway attenuation, monocyte-derived cytokine/chemokine upregulation with enhanced antigen presentation, and neutrophil degranulation suppression.
Trajectory analysis linked these changes to outcomes: IL-1 increases correlated with respiratory failure (OR 1.82 for ≥4 cytokines), reversed by clarithromycin (OR 0.47). Monocyte cytokines (e.g., IFNγ, CXCL8/10, IL-6) surges tied to endpoint success (OR 1.16 per increase), amplified in clarithromycin (OR 1.87 for ≥5). Cholesterol homeostasis and MHC II genes were upregulated, hinting at broader metabolic-immune tuning.Read the full eBioMedicine paper here.
Decoding the Immunomodulatory Mechanisms Step-by-Step
Clarithromycin's magic unfolds via nuanced immune reprogramming. First, it dampens the hyperinflammatory IL-1 cascade—downregulating receptors (IL1R1, IL1R2, IL18R1) and cytokines (IL-1β, IL-18)—preventing ARDS. This contrasts excessive IL-1 in untreated CAP, fueling tissue damage.
Second, it revitalizes monocytes: Upregulating pro-inflammatory signals (GM-CSF, IL-23, calprotectin) and HLA-DMA for antigen presentation, countering immunoparalysis and averting secondary sepsis. PBMC assays confirmed fewer anti-inflammatory suppressors (OR 0.60).
Third, neutrophil degranulation genes (e.g., PADI2) drop, curbing NETosis-driven thrombosis and organ injury. These converge: monocyte boosts inversely link to neutrophil harms, per supplementary data.
- IL-1 attenuation: Reduces respiratory failure risk by 53%.
- Monocyte activation: Doubles odds of early recovery.
- Neutrophil control: Lowers ventilation needs by 65%.
Greek Academic Institutions Driving the Discovery
The study exemplifies Greece's prowess in infectious disease research, led by the National and Kapodistrian University of Athens (NKUA)—Greece's top medical school, ranked #216 globally (US News) and #1 nationally for clinical medicine. Partners included University of Patras, University of Ioannina, and hospitals like Evangelismos and Thriasio. The Hellenic Institute for the Study of Sepsis (HISS), a non-profit CRO founded in 2010, coordinated, leveraging expertise in sepsis immunomodulation.
The Greek Genome Center at BRFAA enabled transcriptomics, showcasing interdisciplinary higher ed collaboration.Learn more about HISS. This network of 18 sites underscores public university-hospital synergies, vital for Europe's research ecosystem.
Spotlight on Prof. Evangelos J. Giamarellos-Bourboulis
Principal investigator Prof. Giamarellos-Bourboulis, from NKUA's 4th Department of Internal Medicine and HISS President, boasts 45,850+ Google Scholar citations, specializing in sepsis pathogenesis and immunomodulation. His career spans pivotal trials, earning the Young Investigator Award. Quoted in the press release: “These data make ACCESS the first CAP trial linking mechanisms to benefits.”
Co-author Emmanouil Stylianakis and international collaborators from Radboud (Netherlands), Bonn (Germany), and Weil Cornell (USA) highlight pan-European ties, amplifying Greek leadership.
Implications for European CAP Guidelines and Practice
ERS/ESICM/ESCMID guidelines already endorse macrolides for severe CAP; ACCESS data bolsters clarithromycin specifically, showing cost savings and reduced ICU stays. Reviews affirm macrolides' neutrophil-reducing, cytokine-balancing effects. In aging Europe, where CAP kills thousands yearly, this could cut hospitalizations 30%.Original ACCESS trial in The Lancet Respiratory Medicine.
Challenges: Antimicrobial resistance; yet clarithromycin's low-dose immunomodulation minimizes selection pressure.
Broader Horizons: Sepsis Research and European Higher Education
Beyond CAP, findings inform sepsis management—IL-1 targeting echoes anakinra trials, monocyte revival combats immunoparalysis. HISS's pipeline promises extensions.
In European higher ed, Greek unis exemplify resilience amid funding woes, securing Abbott grants sans design influence. NKUA's climb to #191 in scientific papers rankings underscores impact. This fosters EU Horizon collaborations, training next-gen researchers in precision immunology.
Future Outlook: Trials, Personalization, and Policy
Ongoing subgroup analyses and economic models from ACCESS predict savings; larger EU trials could validate. Precision: Biomarkers like procalcitonin guide use. Policy-wise, integrate into national guidelines, boosting Greek research visibility.
Stakeholders—ERS, EMA—eye macrolide revival; universities gain from translational success, attracting talent/jobs in med research.Press release on the collaboration.
This eBioMedicine publication cements Greek academia's role in tackling CAP, blending clinical acumen with molecular precision. As Europe grapples with respiratory threats, clarithromycin's validated benefits herald smarter, immune-smart therapies—paving pathways for healthier futures through relentless university-led innovation.
